Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
University of Washington
Prelude Therapeutics
M.D. Anderson Cancer Center
University of California, Irvine
Disc Medicine, Inc
Chengdu Zenitar Biomedical Technology Co., Ltd
Peking Union Medical College Hospital
Incyte Corporation
Merck Sharp & Dohme LLC
University of Southern California
City of Hope Medical Center
Italfarmaco
MPN Research Foundation
Ionis Pharmaceuticals, Inc.
Hospices Civils de Lyon
M.D. Anderson Cancer Center
iOMEDICO AG
Massachusetts General Hospital
University of Miami
M.D. Anderson Cancer Center
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Silence Therapeutics plc
Icahn School of Medicine at Mount Sinai
University Hospital, Angers
Hospices Civils de Lyon
Novartis
Novartis
Thomas Jefferson University
Thomas Jefferson University
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
PharmaEssentia Japan K.K.
Novartis
Incyte Corporation
Hangzhou GluBio Pharmaceutical Co., Ltd.
PharmaEssentia
Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc.
PharmaEssentia
PharmaEssentia
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Barbara Ann Karmanos Cancer Institute
Roswell Park Cancer Institute
UNC Lineberger Comprehensive Cancer Center